These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 33237321)

  • 1. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
    Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs: A Systematic Review and Meta-Analysis.
    Milosavljevic F; Manojlovic M; Matkovic L; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Netw Open; 2024 Aug; 7(8):e2425593. PubMed ID: 39115847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
    Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
    Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.
    Smith RL; Molden E; Bernard JP
    Br J Clin Pharmacol; 2023 Jul; 89(7):2246-2253. PubMed ID: 36851891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
    Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
    J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.
    Austin-Zimmerman I; Wronska M; Wang B; Irizar H; Thygesen JH; Bhat A; Denaxas S; Fatemifar G; Finan C; Harju-Seppänen J; Giannakopoulou O; Kuchenbaecker K; Zartaloudi E; McQuillin A; Bramon E
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of CYP450 testing in the clinical setting.
    Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
    Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
    Kringen MK; Bråten LS; Haslemo T; Molden E
    J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.
    Islam F; Marshe VS; Magarbeh L; Frey BN; Milev RV; Soares CN; Parikh SV; Placenza F; Strother SC; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
    Transl Psychiatry; 2022 Sep; 12(1):366. PubMed ID: 36068210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
    Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
    J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of
    Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
    Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.
    Scherf-Clavel M; Weber H; Unterecker S; Frantz A; Eckert A; Reif A; Deckert J; Hahn M
    Pharmacopsychiatry; 2024 Mar; 57(2):69-77. PubMed ID: 38354747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum concentration and its metabolic ratio in a European patient population.
    Faraj P; Haslemo T; Tran JP; Stingl J; Molden E; Hole K
    Br J Clin Pharmacol; 2024 Oct; 90(10):2630-2637. PubMed ID: 38925553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
    Scherf-Clavel M; Frantz A; Eckert A; Weber H; Unterecker S; Deckert J; Reif A; Hahn M
    Int J Clin Pharm; 2023 Oct; 45(5):1107-1117. PubMed ID: 37166747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
    Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Lee SH; Newhouse S; Patel H; O'Donovan M; Lewis G; Jenkins G; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Schruers K; Biernacka JM; Uher R; Lewis CM
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):945-954. PubMed ID: 30135031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine.
    Chua EW; Foulds J; Miller AL; Kennedy MA
    Pharmacogenet Genomics; 2013 Sep; 23(9):494-7. PubMed ID: 23799451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.